Johnson and Johnson

After three years of waiting, Johnson & Johnson (NYSE: JNJ) shares have returned to trend, a monumental event for the market which presents a potential buying opportunity for income investors. Not only is Johnson & Johnson's business sound but results from competitors like...

The groundhog is about to tell us how much longer winter might last. At the same time, events in February could give investors an idea how much longer COVID-19 might keep the economy’s emergency brake pressed to the floor. Will earnings and data begin to show more signs of recovery from the...

The Horizons Psychedelic Stock Index ETF is now listed on Toronto’s NEO exchange under the symbol ‘PSYK.’ PSYK is the first exchange traded fund providing exposure to the burgeoning industry of medicinal psychedelics. The ETF is managed by Horizons ETFs...

Deep value investor Tim Melvin had the opportunity to speak with Nate Tobik of Complete Bank Data and Oddballstocks.com. Below is a full transcript of their conversation. Benzinga: Hey Nate, how are you doing? Nate Tobik: Good. BZ: Alright. We're on today with Nate Tobik of Complete Bank Data and...

Many analysts, including myself, have been touting Johnson & Johnson (NYSE: JNJ) as a high quality, dividend paying blue chip for the last several months. The company is top quality with very stable, predictable, cash flows and a solid 3.5% dividend yield. In addition the company has upped it'...